Presenter: Leonard Abbeduto, PhD, is the Director of the UC Davis MIND Institute, the Tsakopoulos-Vismara Endowed Chair, and Professor of Psychiatry and Behavioral Sciences at the University of California, Davis. Dr. Abbeduto’s research is focused broadly on the development of language across the lifespan in individuals with neurodevelopmental disorders and the family context for language development. Dr. Abbeduto has published more than 190 articles, chapters, reviews, and books on Down syndrome, fragile X syndrome, autism, intellectual disabilities, and child development. His current research is focused on understanding variation in language outcomes in various neurodevelopmental disabilities, the measurement of treatment effects in clinical trials, and the use of distance technology in behavioral treatment. He serves as director of the NICHD-funded MIND Institute Intellectual and Developmental Disabilities Research Center. Dr. Abbeduto has received numerous awards, including the Steiger Award for Distinguished Teaching from the University of Wisconsin-Madison, the Faculty Stewardship Award from the University of California, Davis, the Enid and William Rosen Research Award from the National Fragile X Foundation, and the Edgar Doll Award for Distinguished Research Contributions from Division 33 of the American Psychological Association. He earned his PhD in psychology from the University of Illinois at Chicago in 1982.
Chicago is one of the world’s most popular marathons and LuMind IDSC has a full team!!!
Visit our Crowdrise page to read the stories on why they run or to donate to the LuMind IDSC team to help raise money to support Down syndrome research.
If you received your own entry to the 2019 Chicago Marathon but still want to fundraise with our team email firstname.lastname@example.org. Didn’t get in this year fill out the following survey to submit your entry for 2020!!
Join LuMind IDSC at the 34th DS ACT Convention on October 19th at the
Water’s Edge Resort and Spa
Stop by our booth to learn more about the exciting research that is getting closer to clinical trials and the new LuMind IDSC initiatives for the Down syndrome community.
James Hendrix, Ph.D., will also be speaking at the social hour at 3:45. Dr. Hendix will be presenting on how the momentum around research for Down syndrome has grown dramatically in recent years. The NIH, the pharmaceutical industry, researchers and clinicians, research-focused foundations, and families are increasingly rallying behind research to spur new treatment options for our loved ones with Down syndrome. There are many novel, promising activities in Alzheimer’s disease, sleep apnea, autoimmune conditions and more. We are entering a time where families and affiliates are now adding research to their most important topics along with education, early intervention inclusion, and advocacy.
He will also provide an update on some research advances, including work supported by the LuMind IDSC Foundation. He will also share reasons and resources for families to rally behind Down syndrome research. Dr. Hendrix is also happy to take questions on Down syndrome research.
To find out more information about the conference, go to the DS ACT website at mydsact.org Our thanks to DS ACT for inviting LuMind IDSC and for the conference committee for their exceptional work organizing this conference.
Thank you to the LuMind IDSC Team who are running at the New York City Marathon on November 3th!
Come down to our cheering station and cheer our runners on please email email@example.com to get more information.
The 2019 North Carolina Down Syndrome Conference covers the lifespan of an individual with Down syndrome and is a valuable resource serving all audiences. The conference includes a plenary speaker, resource exhibits, networking lunch, and 18 breakout sessions that bring information and resources to families, educators, healthcare providers, and older teens and adults with Down syndrome.
Presenter: Jamie Edgin, Ph.D
Dr. Jamie Edgin is a tenured Associate Professor and Co-Director of the Cognition and Neural Systems Program in the Department of Psychology at the University of Arizona. Her research centers on understanding the neurological basis for sleep, memory, and language impairment in developmental disorders, particularly Down syndrome (DS) and autism. She has received several awards for her work in intellectual and developmental disabilities, including the 2018 University of Arizona Koffler Prize, the Charles Epstein award from the National Down Syndrome Society, and the Inaugural David Cox “Rising Star” award from the LuMind IDSC Foundation. She is an expert in Developmental Cognitive Neuroscience, with several published works on sleep, memory, and neuroimaging in typical children, DS, and other at-risk groups. She has >40 published papers employing sleep and neurocognitive assessment, EEG/ERP, fMRI, and eyetracking methodologies in these populations. She serves on several editorial boards for leading national and international journals focused on developmental disability and regularly participates in grant review for various granting agencies. Dr. Edgin’s team has just finished data collection on the first longitudinal study to examine sleep disturbance and development in infants and toddlers with DS from 6-24 months of age. Further, she currently leads a NIH-funded multisite study to design and validate a new neuropsychological assessment tool for use in intellectual disabilities, the “Arizona Memory Assessment for Preschoolers and Special Populations.” She was instrumental in the design and validation of one important battery of cognitive tests validated specifically for use in DS: The Arizona Cognitive Test Battery.
The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. The goal of the meeting is to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments.
Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.
The future of clinical trials may lie in revisiting all drugs known to be safe and evaluate their relevance in AD treatment. We learned at CTAD 2018 of the importance of non-pharmaceutical trials and that anti-amyloid treatment for AD should begin early on in the disease process. Furthermore we also learned more of another pathway with Tau Biomarkers, and their implications for AD along with combination therapeutics and phase 3 clinical trials results. Again in 2019 Clinical teams will present their population studies on subjects in the early stage of the disease or even at the asymptomatic stage.
CTAD 2019 will highlight the latest on trying to get these trials off the ground.
Overall, the aim of the conference is to overcome the hurdles and speed the development of effective treatments.